ERYTECH PHARMA - SPON ADR (ERYP)

US29604W1080 - ADR

0.78  0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
3.718M
-29.62%		4.18M
12.43%		6.648M
59.04%		21.067M
216.89%
EBITDA
YoY % growth
-63.841M
-6.65%		-51.138M
19.90%		-22.528M
55.95%		-27.54M
-22.25%		N/AN/A
EBIT
YoY % growth
-68.832M
-7.43%		-56.515M
17.89%		-27.147M
51.96%		-27.8M
-2.41%
Operating Margin
-1,851.32%-1,352.03%-408.35%-131.96%
EPS
YoY % growth
N/AN/AN/A-0.95N/AN/A

All data in EUR

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 23 Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.19
Revenue
Q2Q % growth		299.88K
-44.36%
EBITDA
Q2Q % growth		N/AN/AN/AN/A
EBIT
Q2Q % growth		-6.314M
49.55%

All data in EUR

Recent Earnings VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q2 2022
Q2Q % growth		 -0.10 -0.520.4280.74%
Recent Revenue VS Estimates Surprises (EUR)
PeriodReportedEstimateDifferenceSurprise
Q4 2022
Q2Q % growth		 5.694M
198.12%		714K4.98M697.48%
Q3 2022
Q2Q % growth		 469K 2.55M-2.081M-81.61%
Q2 2022
Q2Q % growth		 954K
-57.97%		2.55M-1.596M-62.59%
Q1 2022
Q2Q % growth		 539K
-62.57%		2.55M-2.011M-78.86%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 9.09% 0% 9.09%
Revenue0% 0% 0% 0%